Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News


TOP industry news from Business Wire

PPF and SOTIO Invest $6.5 Million in MaveriX Oncology and its Lead Program MVX-5005Open in a New Window

PRAGUE & PALO ALTO, Calif.--(BUSINESS WIRE)--SOTIO, together with PPF, and MaveriX Oncology, Inc., today announce the investment of PPF Group in MaveriX Oncology Inc., a private biotech company with a proprietary pipeline of targeted, small-molecule cancer chemo-immunotherapeutics. PPF has committed to investing $6.5 million in MaveriX Oncology’s ongoing Series A financing contingent on key development milestones. In total, MaveriX is aiming to secure a total of $20 million in funding and the r

 

Advaita’s iPathwayGuide Provides a Cost-effective Alternative to Ingenuity Pathway Analysis (IPA) on Yet Another ContinentOpen in a New Window

ANN ARBOR, Mich.--(BUSINESS WIRE)-- #Bioinformatics--Advaita Bioinformatics partners with inqaba biotec, launching state-of-the-art pathway analysis for life scientists in Sub-Saharan Africa.

 

Mogrify Raises Additional $16 Million to Advance its Mission to Transform the Development of Life-saving Cell TherapiesOpen in a New Window

CAMBRIDGE, England--(BUSINESS WIRE)--Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest. Mogrify is also active

 

Abzena Names Kimball Hall as Chief Operating OfficerOpen in a New Window

SAN DIEGO, Calif.--(BUSINESS WIRE)--Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team. Ms. Hall will focus on the growth of Abzena as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates. She joins Abzena from Genentech, a member of the Roche Group, a leading biopharmaceutical company. She stated, “I am delighted to be join

 

Perspectum宣佈與Precious Medical Centre合作Open in a New Window

新加坡--(BUSINESS WIRE)--(美國商業資訊)--首屈一指的代謝疾病和癌症診斷解決方案提供商Perspectum正與新加坡一流的影像中心Precious Medical合作,在此之前,本週舉行了成功的產品發表活動。 慢性肝病是「無聲無息」且日漸增多的流行病。肥胖症和糖尿病患者愈來愈多已帶動非酒精性脂肪肝疾病(NAFLD)的增加,估計有40%的新加坡人受此影響。NAFLD似乎同樣累及BMI指數低於西方人的亞洲人。多數病患可能在進入晚期、不可逆轉的階段之前未出現症狀。肝病如果能在早期診斷出來,可阻止疾病惡化,減少對昂貴干預的需求。 Precious Medical Centre院長William Chong博士表示:「慢性肝病精準量化方法的開發將幫助改善病患的醫護品質。我們對在亞洲率先臨床應用LiverMultiScan感到自豪。我們希望此次合作亦將引起大家的重視,考慮使肝臟檢查成為健康檢查的重要部分——診斷越早,康復機率就越大。」 Perspectum董事長Michael Brady爵士表示:「我們對於在亞洲診所引進我們的創新產品感到振奮——我們的產品提供可升級、以病患為

 

Perspectum宣布与Precious Medical Centre合作Open in a New Window

新加坡--(BUSINESS WIRE)--(美国商业资讯)--领先的代谢疾病和癌症诊断解决方案提供商Perspectum正与新加坡一流的影像中心Precious Medical合作,在此之前,本周举行了成功的产品发布活动。 慢性肝病是一种“无声无息”且日渐增多的流行病。不断增长的肥胖症和糖尿病水平已推动非酒精性脂肪肝病(NAFLD)的增加,估计累及40%的新加坡人。NAFLD似乎同样累及体重指数低于西方人的亚洲人。多数患者可能在进入晚期、不可逆阶段之前没有症状体验。肝病如果得到早期诊断,其进展能够得到遏制,减少昂贵干预的需求。 Precious Medical Centre院长William Chong博士表示:“慢性肝病精准定量方法的开发将帮助提高我们患者的医护品质。我们对在亚洲率先临床应用LiverMultiScan感到自豪。我们希望此次合作还将引起大家的重视,考虑将肝脏检查作为其健康筛查的组成部分——诊断越早,康复几率就越大。” Perspectum董事长Michael Brady爵士表示:“我们对在亚洲诊所上市我们的创新产品感到振奋——我们的产品提供可升级的、以患者为中心的

 

Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus VulgarisOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF), in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF, with 40.3% of patients treated with Rituxan achieving sustained complete re

 

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic TestOpen in a New Window

LAUSANNE, Switzerland--(BUSINESS WIRE)--Novigenix and RadioMedix collaborate on neuroendocrine cancer precision diagnostic test

 

Novigenix et RadioMedix vont développer un test diagnostic personnalisé pour les tumeurs neuroendocriniennesOpen in a New Window

LAUSANNE, Suisse--(BUSINESS WIRE)--Novigenix SA est une société pionnière dans le domaine de l’Immuno-Transcriptomique, qui développe et commercialise des produits pour la détection précoce du cancer et la médecine de précision, a annoncé aujourd'hui une collaboration avec RadioMedix Inc. une société radiopharmaceutique spécialisée dans la radiothérapie, afin de mettre au point un test diagnostic basé sur une technologie propriétaire de Novigenix. Le test mesurera la réponse immunitaire chez le

 

 Shionogi gibt positive Resultate für klinische Phase-III-Studie von Cefiderocol in Erwachsenen mit nosokomialer Pneumonie aufgrund gramnegativer Pathogene bekanntOpen in a New Window

AMSTERDAM, Niederlande--(BUSINESS WIRE)--Shionogi & Co., Ltd. (im Folgenden „Shionogi”) gibt Ergebnisse aus der APEKS-NP-Studie, einer klinischen, internationalen, doppelblinden, randomisierten Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit des in der Prüfung befindlichen Antibiotikums Cefiderocol in Patienten mit nosokomialer Pneumonie (NP), bekannt. Die Ergebnisse der Studie zeigten, dass Cefiderocol den primären Endpunkt der Nichtunterlegenheit gegenüber einer Meropenem-Ho

 

Association Management Software Powered by YourMembership  ::  Legal